MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations

MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma

(2013) H. Horn et al.   BLOOD

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

(2013) S. Hu et al.   BLOOD

MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

(2013) A. Valera et al.   HAEMATOLOGICA

Double-hit BCL2/MYC translocations in a consecutive cohort of patients with large B-cell lymphoma - a single centre's experience

(2012) Mette Ø. Pedersen et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

(2012) Tina Marie Green et al.   JOURNAL OF CLINICAL ONCOLOGY

Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

(2012) Nathalie A. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

MYC and Aggressive B-cell Lymphomas

(2011) Graham W. Slack et al.   ADVANCES IN ANATOMIC PATHOLOGY

Prognostic significance ofMYC,BCL2, andBCL6rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab

(2011) Nalan Akyurek et al.   CANCER

Rearrangement ofMYCIs Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab

(2010) Sharon Barrans et al.   JOURNAL OF CLINICAL ONCOLOGY

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival

(2009) N. A. Johnson et al.   BLOOD

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy

(2009) K. J. Savage et al.   BLOOD